Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus CLINDAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus CLINDAGEL.
BENZAMYCIN vs CLINDAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, disrupting peptide chain initiation. It may also exhibit anti-inflammatory and immunomodulatory effects via inhibition of neutrophil chemotaxis and phagocytosis.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Apply thin layer to affected area twice daily.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
2-3 hours in patients with normal renal function; clinically significant accumulation may occur in severe hepatic impairment.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Approximately 10% of the dose is excreted renally as unchanged drug; the remainder is hepatically metabolized and excreted in bile and feces. Renal clearance accounts for <1% of total clearance.
Category C
Category C
Topical Antibiotic
Topical Antibiotic